Novavax (NVAX) Up On Positive Influenza Study Results

September 1, 2009 9:34 AM EDT
Novavax, Inc. (Nasdaq: NVAX) is en fuego this morning following positive results on a phase II human clinical trial of its trivalent seasonal influenza virus-like particle (VLP) vaccine candidate.

Shares are up 25% currently on heavy volume.

NVAX is one of the 'it' H1N1 (swine flu) stocks, along with BioCryst (Nasdaq: BCRX) and Vical (Nasdaq: VICL), Sinovac Biotech (NYSE: SVA).

You May Also Be Interested In

Related Categories

Insiders' Blog, Momentum Movers